Loading clinical trials...

Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | Clinical Trials | Clareo Health

WITHDRAWNPHASE1/PHASE2

Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells

Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells

NCT05628545•Guangdong GD Kongming Biotech LLC

Summary

Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients. The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Age is 18-75 years old, and gender is unlimited;
•2. HCC was confirmed by pathological or clinical examination;
•3. Patients with stage CNLCIII, IV primary HCC who are receiving second-line treatment / unable to receive existing treatments, or CNLCI and II of primary HCC patients who are unable to receive existing treatments;
•4. Male subjects with partner women of childbearing age must have reliable, effective methods of contraception starting from the signing of the informed consent form until 120 days after the last dose of the study drug. Male subjects with a pregnant spouse must use condoms without other contraceptive methods;
•5. Participants volunteered to join the study, signed an informed consent, had good compliance, and cooperated with the follow-up.

Exclusion Criteria

•1. Gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, or hepatorenal syndrome;
•2. Accept other cellular or immune clinical experiments within 8 weeks before enrollment;
•3. Immunological deficiency, a known immunosuppressive disease or HIV;
•4. Active infection, unexplained fever;
•5. Serious or unstable heart, lung, kidney and hematopoietic system diseases;
•6. Autoimmune diseases, such as rheumatoid arthritis;
•7. Neurological diseases, diffuse leptomeningeal diseases; combined with neurodegenerative diseases;
•8. Hormone use during cell therapy: dexamethasone dose exceeds 2mg / day during immunotherapy;
•9. Pregnant or lactating women;
•10. The subject had a known history of psychotropic substance abuse or drug use; he had stopped drinking Patients can be enrolled; 11 In the judgment of the investigator, the subject has other factors that may cause the forced termination of the study, such as other serious diseases or serious abnormal laboratory examination or other family or social factors that will affect the subject's safety of the subject, or the collection of trial data and samples.

Locations (1)

Zhuhai People'S Hospital

Zhuhai, Guangdong, China

Key Dates

Start Date

November 1, 2021

Primary Completion Date

February 28, 2023

Completion Date

October 31, 2024

Last Updated

January 18, 2023

Conditions

Advanced Hepatocellular Carcinoma

Interventions

GDKM-100 injection

BIOLOGICAL

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

NCT06811116

Advanced Hepatocellular CarcinomaMetastatic Hepatocellular Carcinoma+2 more

View study

RECRUITINGPHASE1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 18, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells

Inclusion Criteria

Exclusion Criteria

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

HAI or IV of Adebrelimab, Combined with Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma

Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma